2007, Illness and Manufacturing - Primary Care Digest

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

2007

Illness

Manufacturing

Biased research, aggressive sales, harmful drugs

The Health Policy Exchange

MAY 20, 2013

Food and Drug Administration to market a new drug is a critical waypoint along the path to profits for pharmaceutical manufacturers. In the meantime, lobbyists working for the drug manufacturers successfully blocked efforts by Medicare administrators to stop paying for the higher (harmful) doses. Approval from the U.S.

Manufacturing

Manufacturing Family Medicine DO Patients

Court Strikes Down CMS’s Accumulator Adjustment Rule That Threatened Manufacturer Patient Savings Programs

FDA Law Blog

MAY 19, 2022

By Faraz Siddiqui — Last June, we blogged about a lawsuit brought by the Pharmaceutical Research and Manufacturers of America (PhRMA) challenging CMS’s ill-conceived Accumulator Adjustment Rule (“final rule”), which amended the Medicaid Rebate best price regulation. On Tuesday, May 17, 2022, the D.C.

Manufacturing

Manufacturing Patients Insurance Government

Biased research, aggressive sales, harmful drugs

Court Strikes Down CMS’s Accumulator Adjustment Rule That Threatened Manufacturer Patient Savings Programs

Stay Connected